As a tetracycline derivative,<unk>  exhibits similar side effects to the class of antibiotics. Gastrointestinal (GI) symptoms are the most common reported side effect. Common side effects of<unk>  include nausea and vomiting. Nausea (26%) and vomiting (18%) tend to be mild or moderate and usually occur during the first two days of therapy. Rare adverse effects (<2%) include: swelling, pain, and irritation at injection site, anorexia, jaundice, hepatic dysfunction, pruritus, acute pancreatitis, and increased prothrombin time. Precautions Precaution is needed when taken in individuals with tetracycline hypersensitivity, pregnant women, and children. It has been found to cause fetal harm when administered during pregnancy and therefore is classified as pregnancy category D. In rats or rabbits,<unk>  crossed the placenta and was found in the fetal tissues, and is associated with slightly lower birth weights as well as slower bone ossification. Even though it was not considered teratogenic,<unk>  should be avoided unless benefits outweigh the risks. In addition, its use during childhood can cause yellow-grey-brown discoloration of the teeth and should not be used unless necessary. More so, there are clinical reports of<unk> -induced acute pancreatitis, with particular relevance to patients also diagnosed with cystic fibrosis.<unk>  showed an increased mortality in patients treated for hospital-acquired pneumonia, especially ventilator-associated pneumonia (a non-approved use), but also in patients with complicated skin and skin structure infections, complicated intra-abdominal infections and diabetic foot infection. Increased mortality was in comparison to other treatment of the same types of infections. The difference was not statistically significant for any type, but mortality was numerically greater for every infection type with<unk>  treatment, and prompted a black box warning by the FDA. Black box warning The FDA issued a black box warning in September 2010, for<unk>  regarding an increased risk of death compared to other appropriate treatment. As a result of increase in total death rate (cause is unknown) in individuals taking this drug,<unk>  is reserved for situations in which alternative treatment is not suitable. The FDA updated the black box warning in 2013. Drug interactions<unk>  has been found to interact with medications, such as: * Warfarin: Since both<unk>  and warfarin bind to serum or plasma proteins, there is potential for protein-binding interactions, such that one drug will have more effect than the other. Although dose adjustment is not necessary, INR and prothrombin time should be monitored if given concurrently. * Oral contraceptives: Effectiveness of oral contraceptives are decreased with concurrent use due to reduction in the concentration levels of oral contraceptives. However, the mechanism behind these drug interactions have not been fully analyzed.
Tigecycline
Daptomycin
Linezolid
Telithromycin
Delafloxacin
Teicoplanin
Merafloxacin
Doxycycline